Catalent Launches FormProRx to Solve Formulation Challenges
Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, is to launch its new ‘FormProRx’ web tool today during the forthcoming 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
This innovative web-based scientific resource has been exclusively developed by leading Catalent experts to assist drug development teams seeking to determine the optimal finished dose suited to their product based on product requirements, target indications and molecule properties. FormProRx allows users to assess multiple oral drug delivery technologies to establish which may be the most appropriate for their molecule.
Formulators and process development scientists can easily utilise the tool by inputting chemical characteristics and product specifications to generate recommendations based on Catalent’s 75+ years of experience in bioavailability enhancement and applied drug delivery.
Users can gain access to a customised report for their API characteristics and product requirements across 24 dimensions under the categories ‘Solubility & Permeability,’ ‘Physiochemical Properties’, ‘Potent Handling’ and ‘API Processing.’ On completing the profile, the user then immediately receives a detailed report on which drug delivery technologies could be appropriate for further investigation. Whether for a new drug or a line extension, insights from FormProRx may suggest new approaches that benefit pharmacokinetics, patient adherence or the formulation’s therapeutic profile.
"It is ever more challenging to deliver drugs effectively in a form that is convenient for patients and minimises side effects. Formulators can drive better outcomes through familiarity with the many drug delivery technologies available," commented Dr Kurt Nielsen, Chief Technology Officer and Senior Vice President of Innovation and Growth at Catalent. “By introducing a tool that suggests drug delivery technologies based on the specific characteristics of the molecule, and yet is fast and easy-to-use, Catalent aims to help innovators improve their treatments and advance them faster. It is built on the knowledge of many scientists with broad experience developing hundreds of molecules and provides an excellent aid to development teams.”
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance